Sanjay Sharma
Queen Alexandra Hospital
15 Papers
181 Citations
Sanjay Sharma is an academic researcher from Queen Alexandra Hospital. The author has contributed to research in topics: Chemosensitivity assay & Cancer. The author has an hindex of 12, co-authored 15 publications. Previous affiliations of Sanjay Sharma include University of Portsmouth.
Chat about Author
Papers
Cancer cell adaptation to chemotherapy.
Federica Di Nicolantonio,Stuart Mercer,Louise A. Knight,Francis G Gabriel,Pauline A. Whitehouse,Sanjay Sharma,Augusta Fernando,Sharon Glaysher,Silvana Di Palma,Penny Johnson,Shaw Somers,Simon Toh,Bernard Higgins,Alan Lamont,Tim J. Gulliford,Jeremy Hurren,Constantinos Yiangou,Ian A. Cree +17 more
TL;DR: It is suggested that up-regulation of resistance genes or down-regulation in target genes may occur rapidly in human solid tumors, within days of the start of treatment, and that similar changes are present in pre- and post-chemotherapy biopsy material.
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
Sanjay Sharma,Michael H Neale,Federica Di Nicolantonio,Louise A. Knight,Pauline A. Whitehouse,Stuart Mercer,Bernard Higgins,Alan Lamont,Richard H. Osborne,Andrew C Hindley,Christian M. Kurbacher,Ian A. Cree +11 more
TL;DR: The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer, and the assay shows high evaluability and adds weight to the reproducibility of results from different centres.
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
Louise A. Knight,Federica Di Nicolantonio,Pauline A. Whitehouse,Stuart Mercer,Sanjay Sharma,Sharon Glaysher,Penny Johnson,Ian A. Cree +7 more
TL;DR: The in vitro model suggests that gefitinib may have differential effects in response to concomitant cytotoxic chemotherapy with the agents tested during this study, and represents the first use of a TKI in the assay.
Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
Pauline A. Whitehouse,Louise A. Knight,Federica Di Nicolantonio,Stuart Mercer,Sanjay Sharma,Ian A. Cree +5 more
TL;DR: The degree of heterogeneity demonstrated from these results suggests that the ATP-TCA could be used to identify patients who might benefit from specific chemotherapeutic agents alone or in combination.
42
Heterogeneity of chemosensitivity of esophageal and gastric carcinoma.
Stuart Mercer,Shaw Somers,Louise A. Knight,Pauline A. Whitehouse,Sanjay Sharma,Federica Di Nicolantonio,Sharon Glaysher,Simon Toh,Ian A. Cree +8 more
TL;DR: The degree of heterogeneity observed suggests that the ATP-TCA could be used to individualize chemotherapy by selecting agents for particular patients, and provides the rationale for a trial of ATP- TCA-directed therapy to determine whether individualization of chemotherapy might improve patient response and survival.
25